Aprameya EngineeringNSE:APRAMEYA -1.15%41 EBITDA Margin % is 19.99% as of Mar. 2026, which is 60% above its 10-year median of 12.51. GuruFocus rates NSE:APRAMEYA with a GF Score™ of 41/100. The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Aprameya Engineering ranks better than 71.81% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aprameya Engineering EBITDA Margin % Related Terms
Aprameya Engineering EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Aprameya Engineering's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:APRAMEYA vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Aprameya Engineering's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aprameya Engineering EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aprameya Engineering's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aprameya Engineering's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aprameya Engineering (NSE:APRAMEYA) has a EBITDA Margin % of 19.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aprameya Engineering and its competitors. This is 60% above median its historical median of 12.51. Over the past decade, Aprameya Engineering's EBITDA Margin % has ranged from 9.10 to 19.99. According to the industry distribution chart, Aprameya Engineering ranks #230 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 28.2%.
Is Aprameya Engineering's EBITDA Margin % too high?
Aprameya Engineering's current EBITDA Margin % of 19.99% is 60% above median its 10-year median of 12.51. Over the past 10 years, this metric has ranged from a low of 9.10 to a high of 19.99. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Aprameya Engineering's value of 19.99% is 167.4% above this industry median. Based on the distribution chart, Aprameya Engineering ranks #230 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aprameya Engineering has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Aprameya Engineering's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Aprameya Engineering ranks #230 out of 816 companies for EBITDA Margin %. This puts Aprameya Engineering in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Aprameya Engineering's value of 19.99% is 167.4% above this benchmark. Historically, Aprameya Engineering's own EBITDA Margin % has ranged from 9.10 to 19.99 over the past decade. While the company's 10-year median is 12.51 vs. the industry median of 7.48, Aprameya Engineering has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aprameya Engineering's current EBITDA Margin % of 19.99% is 167.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aprameya Engineering and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aprameya Engineering's current EBITDA Margin % is 19.99%, which is 60% above median its own 10-year median of 12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprameya Engineering stock overvalued right now?
Aprameya Engineering (NSE:APRAMEYA) has a current EBITDA Margin % of 19.99%. The current EBITDA Margin % is 19.99%, which is 60% above median its 10-year median of 12.51 and 167.4% above the Medical Devices & Instruments industry median of 7.48. Aprameya Engineering's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aprameya Engineering (NSE:APRAMEYA), the current EBITDA Margin % is 19.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aprameya Engineering Ltd is engaged in the business of installation, set up & maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre, dialysis centres and prefabricated structure ward (hereinafter referred to as Healthcare Infrastructure projects) in the hospitals and medical care centers on turnkey basis with the supply of high-value healthcare equipment and diagnostic equipment to private hospitals, Government hospitals, and medical practitioners. The company has two Business segments: Trading of Medical support Equipment (Trading Sales) and Supplies for Infra Projects for health care sectors (Turnkey project supplies). Key revenue is generated from Trunkey Project Supply.
41GF Score
Get the complete analysis for NSE:APRAMEYA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APRAMEYA has been successfully added to your 